Middle East & Africa Pharmaceutical Gelatin Market Research Report By Function, Source, Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Analysis (2026 to 2034)
The MEA Pharmaceutical Gelatin Market size was valued at USD 1.27 billion in 2024 and is anticipated to reach USD 2.02 billion by 2033, growing at a CAGR of 5.32% from 2024 to 2033. The market is gaining momentum due to the rising demand for remote cardiac care, the growing burden of cardiovascular diseases, and technological advancements in AI-powered diagnostics and wearable cardiac monitoring devices.
The MEA Pharmaceutical Gelatin Market was valued at USD 1.34 billion in 2025, is estimated to reach USD 1.41 billion in 2026, and is projected to reach USD 2.13 billion by 2034, growing at a CAGR of 5.32% from 2026 to 2034.
Pharmaceutical gelatin is a protein derived primarily from collagen found in animal tissues such as bones, skin, and connective tissue. It serves as a vital excipient in the pharmaceutical industry, used extensively in capsule shells, controlled-release formulations, and as a stabilizer in biologics. In the Middle East and Africa (MEA) region, the demand for pharmaceutical gelatin has been steadily rising due to expanding healthcare infrastructure and growing domestic drug manufacturing capabilities.
Additionally, the expansion of local pharmaceutical production in key markets such as South Africa and Egypt has contributed to increased usage of pharmaceutical-grade gelatin. According to the Egyptian Drug Authority, domestic pharmaceutical output grew significantly between 2020 and 2023, supported by government initiatives aimed at reducing import dependency.
The rapid growth of domestic pharmaceutical manufacturing in countries such as Egypt, Saudi Arabia, and South Africa is fuelling the growth of the MEA Pharmaceutical Gelatin Market. These nations have implemented policies to boost local production capacity and reduce reliance on imported medicines, thereby increasing demand for locally sourced excipients like pharmaceutical gelatin. According to the Egyptian Ministry of Health and Population, the country's pharmaceutical industry produced over 95% of its domestic medicine needs by 2023, up from 78% in 2018. In Saudi Arabia, Vision 2030 includes strategic objectives to enhance the national healthcare sector through localized manufacturing. This expansion has led to increased use of excipients, including gelatin, especially in soft and hard capsule production. South Africa, being one of the most developed pharmaceutical hubs in Africa, has also seen a rise in generic drug manufacturing. The South African Health Products Regulatory Authority (SAHPRA) approved over 150 new therapeutic products in 2023 alone.
The rising demand for halal-certified pharmaceuticals and excipients in the GCC and North African countries additionally to propel the growth of the MEA Pharmaceutical Gelatin Market. Consumers and regulators prioritize products that adhere to Islamic dietary laws, which prohibit the use of porcine-derived ingredients. As per the General Authority for Islamic Affairs and Endowments in the UAE, all food and pharmaceutical imports must comply with halal certification requirements before entering the market. In Indonesia though not part of the MEA region the Indonesian Ulema Council (MUI) has set a benchmark for halal certification processes that influence neighboring Muslim-majority countries in Africa.
The limited local production capacity for pharmaceutical-grade gelatin is resulting in heavy reliance on imports from Europe, China, and India, which is likely to hinder the growth of the MEA Pharmaceutical Gelatin Market. According to the African Union's Industrial Development Report, less than 20% of pharmaceutical raw materials used in Africa are sourced domestically. This gap forces manufacturers to depend on international suppliers, leading to higher costs and logistical challenges. For instance, the South African Gelatin Manufacturers Association notes that nearly 85% of the country’s pharmaceutical gelatin is imported, primarily from India and France. This dependence on foreign supplies makes the market vulnerable to price fluctuations, trade disruptions, and extended lead times. Furthermore, customs delays and inconsistent regulatory approvals often hinder the smooth flow of imported gelatin into MEA markets. These bottlenecks increase operational risks for pharmaceutical firms that rely on just-in-time manufacturing models.
The high cost associated with alternative gelatin sources and the certification process required to meet halal and kosher standards are quietly propelling the growth of the MEA Pharmaceutical Gelatin Market. According to the Halal Certification Authority of South Africa, obtaining halal certification involves extensive documentation, facility inspections, and ongoing compliance checks, which can add up to 15% to overall manufacturing expenses. Smaller producers in the MEA region often find these financial and procedural barriers difficult to overcome. Moreover, consumer skepticism about cross-contamination risks during production further complicates the adoption of alternative gelatin sources.
The expansion of the biopharmaceutical and specialty medicine sectors shall create huge growth opportunities for the MEA Pharmaceutical Gelatin Market. Governments in these countries are investing heavily in advanced healthcare infrastructure and encouraging innovation in drug development, which is creating new applications for pharmaceutical gelatin beyond traditional capsule formulations. Saudi Arabia’s Vision 2030 strategy includes a focus on developing a robust biotech industry. According to the Saudi Arabian Biotechnology Association, the country allocated over SAR 3 billion in 2023 to support research and development in life sciences. In Egypt, the National Organization for Drug Control and Research (NODCAR) has approved several new biologic drugs in recent years. South Africa is also witnessing a surge in clinical trials and biologics manufacturing. The South African Medical Research Council reports that over 60 new clinical studies were initiated in 2023, many involving protein-based therapeutics where gelatin plays a role in formulation stability.
The increasing awareness around sustainability, ethical sourcing, and religious dietary preferences, the MEA Pharmaceutical Gelatin Market is witnessing a growing interest in plant-based and microbial gelatin alternatives. This presents a lucrative opportunity for manufacturers willing to innovate and diversify their product offerings to meet evolving consumer and regulatory expectations. Countries like Morocco and Algeria have seen a rise in vegan and vegetarian lifestyles, particularly among younger urban populations. According to a survey conducted by the Arab Vegan Society in 2023, approximately 12% of respondents in North Africa preferred plant-based alternatives in both food and pharmaceutical products. This shift is influencing pharmaceutical companies to explore agar-agar, carrageenan, and pectin-based substitutes that mimic gelatin properties. In addition, scientific institutions across the MEA region are investing in microbial fermentation-based gelatin production. The King Abdullah University of Science and Technology (KAUST) in Saudi Arabia launched a biotech initiative in 2023 focused on synthetic gelatin production using yeast-based fermentation. Moreover, governments are promoting sustainable manufacturing practices.
The technological limitations in producing viable substitutes that match the functional properties of traditional animal-derived gelatin is a key challenging factor for the MEA Pharmaceutical Gelatin Market. While plant-based and microbial gelatin options are gaining traction globally, their adoption in the MEA region is hindered by insufficient R&D infrastructure and technical expertise. According to the African Academy of Sciences, only a handful of research institutions in the region are actively engaged in alternative excipient development, limiting access to cutting-edge formulation techniques. Furthermore, the lack of specialized bioreactors and purification systems necessary for microbial gelatin production restricts large-scale commercialization. In Saudi Arabia, the King Abdulaziz City for Science and Technology (KACST) identified gaps in downstream processing capabilities as a major barrier to scaling up recombinant gelatin production.
Maintaining compliance with stringent quality and safety standards represents another major challenge for the MEA Pharmaceutical Gelatin Market. The gelatin must meet rigorous pharmacopeial guidelines, including those set by the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and International Society for Pharmaceutical Engineers (ISPE). In the Gulf Cooperation Council (GCC) countries, regulatory authorities such as the Saudi Food and Drug Authority (SFDA) and Dubai Municipality enforce strict traceability and purity requirements for imported and domestically produced gelatin. Egypt’s Central Administration for Drug Control (CADC) has also tightened its inspection protocols, mandating BSE-free certification for all animal-derived gelatin imports. South Africa, being a member of the International Council for Harmonisation (ICH), aligns its regulatory framework with global standards, requiring extensive documentation and validation for pharmaceutical excipients. The South African Health Products Regulatory Authority (SAHPRA) mandates multi-stage testing for heavy metals, allergens, and microbial load, increasing compliance complexity for small and medium-sized enterprises (SMEs).
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Function, Source, Application and Country. |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Country Covered | KSA ,UAE ,Israel ,rest of GCC countries, South Africa ,Ethiopia ,Kenya ,Egypt, Sudan, Rest of MEA. |
| Market Leader Profiled | Rousselot, Nitta Gelatin Inc., Capsugel, Catelent Inc., Norland Products Inc |
The gelling agents segment was accounted in holding 42.3% of the MEA Pharmaceutical Gelatin Market share in 2024 with the widespread use of gelatin in capsule manufacturing in hard and soft capsules, which constitute a major portion of pharmaceutical dosage forms in the region. According to the Saudi Food and Drug Authority (SFDA), over 65% of registered oral solid dosage formulations in the GCC require gelatin-based shells, emphasizing its critical role as a gelling agent. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) approved over 180 new capsule-based drugs in 2023, reinforcing the need for high-quality pharmaceutical gelatin. The preference for gelatin stems from its excellent film-forming properties, biocompatibility, and ability to encapsulate both water- and oil-soluble ingredients effectively. Additionally, with increasing investments in local pharmaceutical manufacturing across the MEA region in countries like Egypt and Saudi Arabia, the demand for gelatin as a gelling agent continues to grow steadily, consolidating its position as the leading function in the market.
The stabilizers segment is projected to register a CAGR of 9.4% in the next coming years. This growth is primarily attributed to the rising development and production of biologics, vaccines, and lyophilized injectables that require gelatin to maintain stability during storage and transportation.
Egypt has also emerged as a regional leader in vaccine manufacturing, with the National Research Centre noting that domestic manufacturers produced over 200 million doses in 2023, many of which contained gelatin-based excipients. Similarly, South Africa’s Biopharma Initiative recorded a surge in clinical trials involving protein-based therapeutics, further boosting demand for stabilizers.
The bovine hides segment was the largest by capturing 38.3% of the MEA Pharmaceutical Gelatin Market share in 2024. Saudi Arabia remains a key consumer of bovine hide-based gelatin, with the Saudi Ministry of Environment reporting that over 3.5 million cattle were slaughtered for meat consumption in 2023, generating significant raw material supply for gelatin extraction. In Egypt, the Central Administration for Drug Control (CADC) mandates traceability for all animal-derived excipients, and bovine sources are often more transparent and easier to certify than alternatives.
The fish-based gelatin segment is anticipated to grow with a CAGR of 10.7% from 2025 to 2033. As per the Pew Research Center, over 90% of populations in countries like Morocco, Algeria, and the UAE identify as Muslim, creating a strong demand for halal-certified pharmaceuticals. Fish gelatin provides a viable alternative to porcine or bovine sources without compromising on functional properties. In Egypt, the Islamic Research Council (Dar Al-Ifta) has endorsed fish-derived gelatin for pharmaceutical use, encouraging local manufacturers to adopt it in their formulations. According to the General Authority for Fisheries Resources Development, Egypt generated over 600,000 metric tons of fishery waste in 2023, much of which was repurposed into value-added products such as gelatin. Similarly, in the UAE, Dubai Municipality has been promoting sustainable sourcing practices, including the utilization of marine by-products.
The soft capsules segment held 36.4% of the MEA Pharmaceutical Gelatin Market share in 2024 with the rising popularity of softgel formats in nutraceuticals, hormone therapies, and lipid-based formulations, particularly in Gulf Cooperation Council (GCC) countries and Egypt. According to the Arab Pharmaceutical Manufacturers Association (APMA), the demand for soft capsules in the Middle East increased by 15% in 2023 compared to the previous year, driven by growing health consciousness and increased availability of over-the-counter supplements. Egypt has also seen a surge in domestic soft capsule production, with the Egyptian Drug Authority recording a 20% year-on-year increase in soft capsule manufacturing volumes. Local companies are increasingly using gelatin sourced from halal-certified bovine and fish origins to meet religious preferences. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) approved several new soft capsule formulations targeting chronic diseases such as diabetes and hypertension.
The microencapsulation segment is lucratively to register a CAGR of 11.5% during the forecast period with the increasing use of microencapsulated APIs in controlled-release formulations, targeted drug delivery, and flavor-masking applications, particularly in chronic disease management and pediatric formulations. In Saudi Arabia, the King Abdulaziz City for Science and Technology (KACST) reported that over 25 new microencapsulation-based drug projects were initiated in 2023, focusing on gastro-resistant and time-released formulations. Egypt has also made notable strides in this area. The National Research Centre (NRC) collaborated with local pharmaceutical firms to develop gelatin-based microcapsules for anti-inflammatory drugs, enhancing solubility and absorption rates. In South Africa, the Medical Research Council (SAMRC) supported multiple clinical trials involving microencapsulated antiretroviral drugs aimed at improving HIV treatment regimens.
Saudi Arabia was the largest contributor 25.4% of the MEA Pharmaceutical Gelatin Market share in 2024. This growth has been accompanied by increased demand for excipients such as pharmaceutical gelatin, particularly in capsule and biologic formulations. Moreover, the Halal Certification Authority of the UAE plays a pivotal role in certifying gelatin used in Saudi pharmaceuticals, ensuring compliance with Islamic dietary laws.
Egypt was the positioned next MEA Pharmaceutical Gelatin Market with a 18.3% of share in 2024. Egyptian pharmaceutical companies rely heavily on gelatin for capsule manufacturing, particularly in the generic and nutraceutical sectors. According to the Egyptian Ministry of Health, capsule-based formulations accounted for nearly 40% of all locally manufactured medicines in 2023. Additionally, the country has become a regional hub for halal-certified pharmaceutical exports, catering to markets in North Africa and the Middle East. The Islamic Research Council (Dar Al-Ifta) has endorsed fish-based gelatin by encouraging its adoption among manufacturers seeking broader export opportunities.
The UAE pharmaceutical gelatin market growth is driven by its advanced healthcare system and strategic focus on pharmaceutical imports and local production. The country serves as a major distribution hub for pharmaceutical products entering the Middle East and beyond. The UAE is also witnessing growing interest in plant-based and microbial gelatin alternatives. The Dubai Future Foundation launched a biotech initiative in 2023 to explore synthetic gelatin production for pharmaceutical use, which is signaling a shift toward innovative and sustainable sourcing methods.
South Africa Pharmaceutical Gelatin Market growth is driven by its well-developed pharmaceutical industry and regulatory framework. The country is home to several large-scale pharmaceutical manufacturers that rely on excipients like gelatin for capsule and biologic formulations. South Africa also plays a crucial role in supplying raw materials for gelatin production to other African nations.
Israel Pharmaceutical Gelatin Market growth is driven by its world-class biotechnology and pharmaceutical research ecosystem. The country is known for its innovation in drug delivery systems, where gelatin plays a key role in microencapsulation and biologics stabilization. The Ministry of Health in Israel enforces stringent quality controls, ensuring that all pharmaceutical excipients meet European and U.S. pharmacopeial standards. Additionally, collaborations between academic institutions and private companies have led to breakthroughs in gelatin-based drug formulations.
Rousselot, Nitta Gelatin Inc., Capsugel, Catelent Inc., Norland Products Inc, Tessenderlo Group, Sterling Gelatin, Roxlor LLC, Weishardt, and Gelita AG are a few of the promising companies operating in the pharmaceutical gelatin market in the MEA region.
The competition in the MEA Pharmaceutical Gelatin Market is shaped by a mix of established global players and emerging regional suppliers striving to capture a stronger foothold in a rapidly evolving industry. This has led to intensified rivalry among suppliers seeking to differentiate themselves through product innovation, purity standards, and customization capabilities. Companies are increasingly focusing on sustainability, ethical sourcing, and halal certification to align with consumer expectations and regulatory norms. At the same time, the push toward alternative gelatin sources is prompting firms to invest in research and development to stay ahead in the market. With increasing scrutiny around raw material sourcing and traceability, competitive positioning now hinges not only on pricing but also on compliance, transparency, and the ability to offer halal-, kosher-, and vegan-certified options.
One of the leading players in the MEA Pharmaceutical Gelatin Market is Rousselot is a global supplier of high-quality gelatin solutions for pharmaceutical applications. The company has a strong presence across the Middle East and North Africa, where it supplies halal-certified bovine and fish-based gelatin to major drug manufacturers. Rousselot is known for its innovation in alternative gelatin sources and invests heavily in R&D to meet evolving regulatory and consumer demands.
Weishardt Group is a France-based company with a growing influence in the MEA region. Weishardt offers customized gelatin products tailored for pharmaceutical uses, including capsule coatings and controlled-release formulations. Its strategic collaborations with regional manufacturers have helped expand its footprint in Egypt and the Gulf Cooperation Council (GCC) countries.
PB Gelatins is a division of Darling Ingredients, which provides pharmaceutical-grade gelatin sourced from multiple origins. PB Gelatins plays a vital role in supplying excipients to MEA markets by ensuring traceability, compliance, and quality assurance. The company’s focus on ethical sourcing and sustainability aligns well with the region’s religious and dietary preferences, which is strengthening its market position.
Product diversification through alternative gelatin development is one of the most important strategy in the MEA Pharmaceutical Gelatin Market. Companies are investing in research to produce plant-based, microbial, and fish-derived gelatin to meet diverse religious and dietary preferences, especially in Muslim-majority countries.
Another prominent approach is strategic collaborations and partnerships with regional pharmaceutical manufacturers. The gelatin suppliers ensure consistent demand and gain insights into specific formulation requirements by enhancing their ability to offer tailored solutions.
The expanding production facilities and strengthening supply chain networks across the MEA region . Manufacturers are setting up new processing units or working with regional distributors to reduce dependency on imports, improve cost efficiency, and ensure timely delivery of high-quality gelatin to pharmaceutical clients.
In February 2025, Rousselot launched a new line of halal-certified fish-based gelatin specifically designed for pharmaceutical use in the Middle East, which is targeting the growing demand for non-porcine excipients in Saudi Arabia and the UAE.
In July 2025, Weishardt Group expanded its distribution network in North Africa by entering into a partnership with an Egyptian pharmaceutical ingredients distributor to enhance accessibility and responsiveness to local manufacturers.
In November 2025, PB Gelatins introduced a dedicated technical support team for MEA clients , offering formulation guidance and regulatory assistance to help pharmaceutical companies navigate halal certification processes.
In March 2025, Gelita AG collaborated with a GCC-based contract manufacturing organization to co-develop customized gelatin solutions for softgel capsule production by reinforcing its presence in the fast-growing nutraceutical and generic medicine sectors.
In August 2025, Nitta Gelatin Inc. opened a regional customer service center in Dubai , aimed at providing localized support for pharmaceutical clients across the Middle East, including application testing and quality assurance services.
This research report on the MEA pharmaceutical gelatin market has been segmented and sub-segmented into the following categories.
By Function
By Source
By Application
By Country
Frequently Asked Questions
Key contributors include Saudi Arabia, UAE, Egypt, South Africa, and Nigeria, driven by growing pharmaceutical infrastructure, healthcare spending, and contract manufacturing.
Hard and soft gelatin capsules Tablet binding agents Coatings Wound care products Hemostatic sponges
Rising elderly population and chronic diseases Growing pharmaceutical production in MEA Increasing awareness of nutraceuticals Favorable government healthcare reforms
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region